Tenofovir (Viread)

Prescribing Information Articles on Tenofivir (Viread) VIREAD® (tenofovir disoproxil fumarate) is a type of medicine called a nucleotide analog reverse transcriptase and hepatitis B virus (HBV) polymerase inhibitor (NRTI). VIREAD is used to treat chronic hepatitis B (an infection with HBV) in adults age 18 years and older. VIREAD works by interfering with the normal working of an enzyme (HBV DNA polymerase) that is essential for the HBV to reproduce itself. VIREAD may help lower the amount of hepatitis B virus in your body by lowering the ability of the virus to multiply and infect new liver cells.

Articles on Tenofovir (Viread)

Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?
6/05/09

Tenofovir (Viread) Is Similarly Effective in Chronic Hepatitis B Patients Regardless of Liver Cirrhosis Status
5/08/09

Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B
5/05/09

Evolution of Viral Load and Genome Sequence in a Clinical Trial of Tenofovir/Emtricitabine Combination Versus Tenofovir Monotherapy for Patients with Previous Adefovir Dipivoxil Failure
4/24/09

Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil
4/24/09

Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF)
4/24/09

Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients
4/24/09

Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB)
4/24/09

Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis
4/24/09

Tenofovir (Viread) Produces Continued HBV Suppression through 96 Weeks in HBeAg Positive and Negative Patients: Studies 102 and 103
11-05/2008

Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102)
11-05/2008

Week 96 Resistance Surveillance for HBeAg Positive and Negative Subjects with Chronic HBV Infection Randomized to Receive Tenofovir DF 300 mg QD
11-05/2008

Tenofovir is Equally Active In Vitro Against Wild-type HBV Clinical Isolates of Genotypes A-H
11-05/2008

Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA
11-05/2008

PRESENCE OF rtA194T AT BASELINE DOES NOT REDUCE EFFICACY TO TENOFOVIR (TDF) IN PATIENTSWITH LAMIVUDINE (LAM)-RESISTANT CHRONIC HEPATITIS B
11-05/2008

Tenofovir Disoproxil Fumarate (TDF) versus Adefovir Dipivoxil (ADV) in Asians with HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Participating in Studies 102 and 103
11-05/2008

Tenofovir (Viread) Effective against Entecavir-resistant Hepatitis B Virus
8/26/2008

FDA Approves Gilead's Tenofovir (Viread) for Treatment of Chronic Hepatitis B
8/15/08

Pharmasset Announces New Trial to Study Clevudine plus Tenofovir (Viread) for Chronic Hepatitis B
7/11/08

Tenofovir (Viread) Demonstrates Good Efficacy and Tolerability in Hepatitis B Patients with Compensated Liver Cirrhosis
5/13/08

Tenofovir May Be More Effective and Less Expensive than Lamivudine (Epivir-HBV) and Adefovir (Hepsera) as First-line Treatment for HBeAg- Chronic Hepatitis B
5/09/08

Tenofovir (Viread) Is Effective in Chronic Hepatitis B Patients with Prior Nucleoside/nucleotide Experience
5/09/08


Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102)
4/29/08